buying a cancer drug startup and sanofi making an offer for the biotech company medevation. meg terrell has the details and why there may be more deals to come. >> reporter: not bad for a thursday. three deals or potential deals totally more than $40 billion were announced in the health care space. some wonder if it spells a turnaround for the sector's recent woes. >> if you've looked at biotech values they're down 35% off the top in the last six to eight months on political rhetoric. asset prices have come down and become a lot more attractive. >> reporter: the biggest health care deal of the day, abbott laboratories' $25 billion fur of st. st. jude medical. abbott cardiovascular service and st. jude together will of that revenue of more than $8.5 billion. the company says it's expanding in the area as 40% of american adults are projected to have some form of card vascular disease by 2030. more dailies could be in the offing. >> i think this is going to trigger a lot more consolidation in med tech space as companies try to compete with j&j, which has long been the dean of t

also biotech company medevation has turned down their unsolicited $9.3 billion offer saying the amount undervalues the company. shares of anna fee fell 4%. >>> roby will buy tivo in a deal valued at more than $1 billion. the new company will take the name tivo. tivo was up nearly 6% to $9.98. shares of rovy up were over 1.5% to 17.62. >>> the drugmaker valiant announced it has finally filed its financial report for 2015. avoiding thereby a default on some of its debt. the report was initially delayed over accuracy concerns with the company's financials. valiant also nominated three new members to its board of directors. shares of valiant nonetheless down more than 5% on the day to 33.36. >>> our market monitor has listed blue chip stocks he says will rise 15% over the next 18 to 24 months. joining us tonight is gary bradshaw, portfolio manager at hodges capital management. the last time he was on in may he recommended brinker international which is down 17%. cracker barrel which is up 5%. and casey's general store up nearly 24%. gary, welcome back. >> two of three is pretty good. >> th

the 5250 bid is the same and here they are making it public for medevation. it's not that large after preemup over medivation. >> you have a $5.8 billion deal and we can't even get to it. the health care consolidation -- it's like a gun went off. you have valiant go down there and a guy's wears his hair shirt saying listen -- at the same time you have major companies making a deal, abbott making a deal. when will pfizer come back? >> moments ago you thought the valiant was the peak of negativity. >> it's like february 10 when we got the bottom of the market because bernie sanders won in new hampshire. when they're in front of congress, that tends not to be the beginning. it tends to be the end. how about the fact he apologized for higher earnings per share? someone apologized for raising numbers, valiant. >> some of the stuff they did was pretty egregious. >> you think, huh? >> i do, i do. i saw what they did with salient. >> i can tell you stories about that but i'm not going to tell because it's personal. this is an amazing market. remember yesterday what w

companies may be richly valued, when you look at a deal like santa fe now cross border hostile for medevationit looks like they're willing to pay up for companies they want. do you think that company wouldn't be a willing seller at the right price and that they wobbling to pay that price? >> you know, a lot of the larger pharmas are desperate for pipeline. to michael's point, they need products. and so they're one of them. astrozenica. they'll pay up. i'm not sure overpaying for an asset is a great strategy. you can wind up in a lot of trouble. so, yes, it will happen. but i think it will happen in a strategic way, not in a sort of stampede way. >> michael, when you look out there in your coverage universe, you gave us some names you think could be takeout candidates. we appreciate that. is there one name out there that may not be a takeout candidate but you're watching them closely now and saying, hey, down the line, they're going to be really, really valuable? >> yeah. so we would say kite another one. kite has phase three cancer assets in the pipeline. and they're hanging out there, too. i